|
|
| Friday, November 7 |
| Session 1 |
Biology of cll |
|
| 14:00-14:30 |
An overview of CLL Biology |
Speaker pending |
| 14:30-15:00 |
IgV usage in CLL |
K. Stamatopoulos (Asvestahori) |
| 15:00-15:30 |
Micro-RNAs in CLL |
G. Adrian-Calin (Houston) |
| 15:30-16:00 |
Coffee break and poster viewing |
|
| Session 2 |
DIAGNOSIS OF CLL |
|
| 16:00-16:30 |
SLL/CLL in the new WHO classification |
A. Martinez (Barcelona) |
| 16:30-17:00 |
Gene expression profile in CLL |
R. Foà (Rome) |
| 17:00-17:30 |
The boundaries of CLL (MBL) |
A. Rawstron (Leeds) |
| 17:30-18:00 |
CLL Transformation (Richter's syndrome and beyond) |
S. Molica (Catanzaro, Italy) |
| 18:00-19:00 |
Interactive poster session with conference faculty |
|
| 20:00 |
Welcome cocktail |
|
| Saturday, November 8 |
| Session 3 |
PROGNOSIS MARKERS |
|
| 09:00-09:30 |
Prognosis markers vs. response predictors: A time for a change has come |
E. Montserrat (Barcelona) |
| 09:30-10:00 |
CLL Prognosis: ZAP-70, IgV mutations, both of them or none of them? |
L. Rassenti (San Diego) |
| 10:00-10:30 |
What does CD38 tell us about CLL? |
S. Deaglio (Torino) |
| 10:30-11:00 |
Coffee break and poster viewing |
|
| 11:00-11:30 |
Genomic abnormalities in CLL: Impact on prognosis and response to therapy |
S. Stilgenbauer (Ulm) |
| Session 4 |
TREATMENT |
|
| 11:30-12:00 |
How to envisage therapy of a patient with CLL in 2008? |
P. Hillmen (Leeds) |
| 12:00-12:30 |
Front-line therapy in CLL: Which type of evidence do we need? |
M. Keating (Houston) |
| 12:30-13:30 |
Lunch |
|
| 13:30-14:00 |
Second-line therapy in CLL: Opportunities anf Pitfalls |
F. Bosch (Barcelona) |
| 14:00-14:30 |
CLL Therapy in elderly patients: How to make progress? |
B. Eichhorst (Cologne) |
| 14:30-15:00 |
New Agents for CLL Therapy: Which are ready for prime time? |
A. Chanan-Khan (Buffalo) |
| 15:00-15:30 |
Coffee break and poster viewing |
|
| 15:30-17:30 |
Short communications |
|
| 18:00-19:00 |
Interactive poster session with conference faculty |
|
| 20:30 |
Gala Dinner |
|
| Sunday, November 9 |
| 09:00-09:30 |
Are stem-cell transplants necessary to achieve MRD - negativity in CLL? |
C. Moreno (Barcelona) |
| 09:30-10:00 |
New trends in CLL Therapy: How to use normal cells to kill neoplastic CLL cells |
J. Gribben (London) |
| Special Session |
|
|
| 10:00-10:30 |
The new IWCLL Guidelines for CLL: What is for clinical practice and what is for trials? |
M. Hallek (Cologne) |
| 10:30-11:00 |
Coffee break |
|
| Session 5 |
JOINING EFFORTS IN CLL INVESTIGATION |
|
| THE USA PERSPECTIVE |
|
|
| 11:00-11:30 |
The CLL Research Consortium (CRC) and the CLL Global Foundation |
M. Keating (Houston) |
| THE EUROPEAN PERSPECTIVE |
|
|
| 11:30-12:00 |
The European Research Initiative for CLL |
P. Ghia (Milan) |
| |
|
|